Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil’s Spiraling Access Suits And The Potential Impact On Companies

Executive Summary

Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.

You may also be interested in...



Biotechs Choosing Brazil For Drug Development And Early Sales

Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.

Brazil Sets Sights On Biogen’s Spinraza For First Risk Sharing Deal

As Brazil turns to risk sharing agreements to improve access to expensive treatments, the health ministry has its eye on Biogen’s rare disease treatment Spinraza (nusinersen).

England’s Innovative Medicines Fund To Put Spotlight On Rare Disease Treatments

While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.

Topics

UsernamePublicRestriction

Register

SC099812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel